Impact of Cardiac Computed Tomographic Angiography Findings on Planning of Cancer Therapy in Patients with Concomitant Structural Heart Disease

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Invasive angiography contraindications</td><td align="center"><i>N</i> (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Low to moderate probability for CAD*</td><td align="center">49 (61.3)</td></tr><tr><td align="left">Leucopenia/thrombocytopenia</td><td align="center">15 (19.2)</td></tr><tr><td align="left">Concomitant chemotherapy or radiation</td><td align="center">20 (25.0)</td></tr><tr><td align="left">≥1 above contraindication</td><td align="center">72 (90)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>
              *CAD: coronary artery disease.<br/>Contraindications are not mutually exclusive.<br/></td></tr></table>

 Relative contraindications for invasive coronary angiography.

Cardiology Research and Practice

tab3

Table 3

Table 3: Impact of Cardiac Computed Tomographic Angiography Findings on Planning of Cancer Therapy in Patients with Concomitant Structural Heart Disease 

Table 3 | Impact of Cardiac Computed Tomographic Angiography Findings on Planning of Cancer Therapy in Patients with Concomitant Structural Heart Disease 